Hikma Pharmaceuticals Plc · LSE:HIK
Hikma Pharmaceuticals — Investor Day (May 2025)
68 slides from Hikma Pharmaceuticals's investor day presentation, May 15, 2025
Slide 1: Better health. Within reach. Every day.
Better health. Within reach. Every day. Hikma US Meet the Management, Columbus Ohio 15 May 2025 Hikma Pharmaceuticals PLC
Slide 2: Disclaimer
Disclaimer Save to the extent required by law, neither Hikma Pharmaceuticals PLC nor any of its affiliates (Hikma), nor any other party, is under any duty to update or inform you of any changes to such information. In particular, it should be noted that the financial information relating to Hikma co
Slide 3: Hikma Rx
Better health. Within reach. Every day. Hikma US Meet the Management Hikma Rx
Slide 4: Presenting team
Presenting team Hafrun Kristy Chris Brett Mike Tyson Fridriksdottir Ronco Edlin Bukvic Balog Ardo President, Chief Commercial VP R&D, AVP BD & Product Sr VP Operations, AVP Quality, Hikma Rx Officer, Hikma Rx Hikma Rx Selection, Hikma Rx Hikma Rx Hikma Rx Hikma Pharmaceuticals PLC 4
Slide 5: Introducing Hikma Rx
Introducing Hikma Rx We are renaming our Generics business division As of today, Generics will become: Rationale: Hikma Rx To better reflect our focus on providing differentiated and complex prescription (Rx) medicines. Hikma’s three business divisions: Hikma Pharmaceuticals PLC 5
Slide 6: Why Columbus?
Columbus, Ohio Why Columbus? ▪ Within a one-day drive over 150 million people can be reached from Columbus – 46% of the US population and 48% of headquarters operations One Columbus ▪ First among the 10 largest Midwest Metro for population, job and GDP growth One Columbus ▪ Ohio ranked 10th for Amer
Slide 7: Agenda
Agenda Introduction Manufacturing R&D and Business Development Commercial Wrap-up Q&A Hikma Pharmaceuticals PLC 7
Slide 8: Agenda
Agenda Introduction Manufacturing R&D and Business Development Commercial Wrap-up Hikma Pharmaceuticals PLC 8
Slide 9: Our high-quality Hikma Rx business
Our high-quality Hikma Rx business • US-based manufacturer and supplier of oral, nasal, Hikma Rx respiratory and other generic and specialty products to the North American retail market 33% of 2024 Revenue • Broad and increasingly complex generic and specialty product portfolio 21% of 2024 Core oper
Slide 10: A differentiated platform to drive long-term success
A differentiated platform to drive long-term success A talented and highly capable team that knows how to compete and win Strong and expanding R&D team with multiple new programs launched Building on Hikma Rx Large and expanding US-based manufacturing competitive and development capabilities strengt
Slide 11: Delivering on promised strategic and tactical initiatives
Delivering on promised strategic and tactical initiatives 2021 Meet the Management | Achievements 2025+ priorities Near-to-medium term priorities Long-term priorities • Identify strategic inorganic growth Acquired high-value ANDAs and • Business Development: augment opportunities, including licensin
Slide 12: Agenda
Agenda Introduction Manufactruing R&D and Business Development Commercial Wrap-up Hikma Pharmaceuticals PLC 12
Slide 13: Uncompromising quality culture with proven track record
Uncompromising quality culture with proven track record Over a decade of excellent audit and inspection results DEA FDA BEL FDA FDA zero observations training FDA FDA FDA RUS KR FDA DEA DEA FDA RUS QMM DEA FDA FDA FDA FDA FDA FDA DEA FDA FDA KZ training training training training FDA DEA FDA FDA FDA
Slide 14: Our facility and expansion plans (recent and future)
Our facility and expansion plans (recent and future) Dedicated potent CMO solids (in progress) You are Respiratory here! Core facility (1m ft2) Materials warehouse (under review) Hikma Pharmaceuticals PLC 14
Slide 15: Significant capacity and differentiated capabilities
Significant capacity and differentiated capabilities Solid Dose High Containment Dry Powder Inhaler Nasals / Liquids (“White Tablet”) (HCO) (DPI) • Charging suites • 1000-4000L stationary • Fully-enclosed equipment • Fluticasone/salmeterol • Zanchetta granulators processing tanks • Ribbon blenders •
Slide 16: Select products manufactured at our Columbus facility
Select products manufactured at our Columbus facility “White tablets” (solids) More differentiated products Dexamethasone Fluticasone Propionate/ Salmeterol Inhalation Powder (generic Advair®) Kloxxado®1 Buprenorphine; (8mg naloxone) Buprenorphine/Naloxone Furosemide Fluticasone Propionate Nasal Spr
Slide 17: Our distribution centers are strategically located to serve key customers
Our distribution centers are strategically located to serve key customers Creekside Wilson Rd. Finished goods & ram materials Material • Room temperature types • Cold Chain Vault 18,000 ft2; Size 275,000 ft2 Starting material 50,000 ft2 Temperature Mapped with full Mapped with 2 2 miles miles contro
Slide 18: Growing CMO business
Growing CMO business Attractive CMO offering Expect CMO contribution to grow over the next 5 years State-of-the-art manufacturing facility in Columbus Ohio FDA/EMA-licensed facility with ability CMO revenue is to ship internationally expected to be On-site product and analytical development and qual
Slide 19: Agenda
Agenda Introduction Manufacturing R&D and Business Development Commercial Wrap-up Hikma Pharmaceuticals PLC 19
Slide 20: Leveraging our global footprint and highly skilled teams to advance our R&D programmes
Leveraging our global footprint and highly skilled teams to advance our R&D programmes Columbus, Ohio, US Berkely Heights, Zagreb, Croatia Amman, Jordan • R&D + RA + BD/Pipeline New Jersey, US • Newly established R&D • R&D in Bayader and Sahab • Focus on complex products • RA, BD/Pipeline • Initial
Slide 21: Business Development
Product selection: utilising internal capabilities and business development to build a robust pipeline Subject-matter expert Utilize network of three development sites input/diligence • Columbus: complex dosage forms (e.g., DPIs, nasals), controlled substances Internal Key decision • Amman: global p
Slide 22: Our pipeline
Our pipeline Key pipeline metrics Development phase Dosage form Filing type 20% Approved / 4% 9% Ophthalmic Tentatively Nasal approved 38% 11% Respiratory Non-p. IV 9% Liquid 24% 62% 56% Filed P. IV Development 13% 55% ER solid IR solid Late-phase assets complemented by Balance of solid orals (compr
Slide 23: Expanding our pipeline of higher-value first wave launches
Expanding our pipeline of higher-value first wave launches First-to-file paragraph IV applications Follow-on paragraph IV applications Reference listed drug Market size Number Reference listed drug Market size Number Status Status (molecule) ($m)1 of filers2 (molecule) ($m)1 of filers2 Vyndamax® Jak
Slide 24: Investing in highly-differentiated generic respiratory platforms
Investing in highly-differentiated generic respiratory platforms 1 Generic Respimat® SMI1 2 Generic Ellipta® DPI2 3 LGWP pMDIs3 ▪ Strategic rationale: ▪ Strategic rationale: ▪ Strategic rationale: few firms capable of successfully ability to leverage gAdvair propellant transition represents developi
Slide 25: Increased emphasis on complex generics to add sustainable value
Increased emphasis on complex generics to add sustainable value 1 New technologies 2 Modified and extended release 3 Nasal sprays ▪ Liquid-filled capsules ▪ Higher barrier-to-entry products ▪ Building on solid commercial foundations ▪ Soft-gel capsules ▪ Expanding internal technology ▪ Installing ne
Slide 26: Agenda
Agenda Introduction Manufacturing R&D and Business Development Commercial Wrap-up Hikma Pharmaceuticals PLC 26
Slide 27: Competing in a changing regulatory and market landscape
Competing in a changing regulatory and market landscape Vertical Alignment within the US Hikma in a strong position Distribution Channels ▪ Strong reputation as a high-quality, consistent supplier ▪ US based manufacturing within close proximity to customers Evolving regulatory and market dynamics ▪
Slide 28: Customers continue to select Hikma as their supplier of choice
Customers continue to select Hikma as their supplier of choice Percentage of portfolio Percentage of portfolio by number of competitors by Hikma market share position 13% 9% Number of 9% Hikma market 9% 5% competitors: share position: 30% 1 1 39% 2 2 30% 3-5 3-5 30% 6-9 6-9 27% 10+ 10+ Hikma establi
Slide 29: Select products contributing to Hikma's success
Select products contributing to Hikma’s success Sodium Oxybate Fluticasone Salmeterol Fluticasone (OTC + Rx) Albuterol (Proventil®) (generic Advair®) • Current authorized generic for Jazz, • Proactively capitalized on accelerated • Continuing to see increased OTC • Growth through conversion as the 6
Slide 30: Leveraging our US capabilities to drive synergies and success
Leveraging our US capabilities to drive synergies and success Integrated market approach: Adapting to evolving market Growth and relationship building: Driving growth through diverse dynamics by merging traditional channel lines, creating a unified and specialty launches, while strengthening relatio
Slide 31: Agenda
Agenda Introduction Manufacturing R&D and Business Development Commercial Wrap-up Hikma Pharmaceuticals PLC 31
Slide 32: Hikma Rx – well positioned for the future
Hikma Rx – well positioned for the future Our strategy positions Hikma Rx for continued near-term success, with an acceleration in profitability over the longer-term Hikma Pharmaceuticals PLC 32
Slide 33: Injectables
Better health. Within reach. Every day. Hikma US Meet the Management Injectables
Slide 34: Presenting team
Presenting team President, Chief Commercial Associate VP, SVP, VP, Injectables Officer, US Injectables Commercial Europe Operations R&D Hikma Pharmaceuticals PLC 34
Slide 35: Agenda
Agenda Introduction R&D Manufacturing North America commercial Europe Wrap-up Hikma Pharmaceuticals PLC 35
Slide 36: Agenda
Agenda Introduction R&D Manufacturing North America commercial Europe Wrap-up Hikma Pharmaceuticals PLC 36
Slide 37: Three high quality businesses
Three high quality businesses Diversity through three distinct business units Hikma Rx 33% 21% • Supplier of generic and specialty injectable products to hospitals across North America, MENA and Europe 42% of 2024 Revenue • >$1.3 bn revenue (2024), 8% five-year revenue 56% of 2024 Core operating pro
Slide 38: A world-class, high growth, defensible Injectables business
A world-class, high growth, defensible Injectables business Through consistent delivery of profitable growth, we are striving to become second largest injectables company by value and volume in the US, top five injectables company in Europe and leading supplier of injectables in MENA. Pipeline Manuf
Slide 39: Agenda
Agenda Introduction R&D Manufacturing North America Commercial Europe Wrap-up Hikma Pharmaceuticals PLC 39
Slide 40: A global footprint with a skilled team of R&D experts
A global footprint with a skilled team of R&D experts Bedford Zagreb Jordan R&D Centers of Excellence with unique skill • Drug-Device Combo • Ready-to-use • Conventional sets, focusing on a range of technology products innovative platforms platforms. products • Depots • MENA R&D (bags, vials, (suspe
Slide 41: R&D strategic pillars
R&D strategic pillars Strategic pillars Strategy in action Diversified pipeline of >160 projects globally1 Increase • Continue to expand pipeline of conventional products, which Differentiated BLA Complex breadth enhance portfolio breadth. 3% • Adding differentiated Ready to Use (RTU) products throu
Slide 42: Expanding our R&D capabilities by adding new technologies
Expanding our R&D capabilities by adding new technologies Complex • 505(b)(2) Long-Acting Autoinjectors Complex APIs Injections • Innovative Bags Differentiated • Milled suspensions • Hormones • Oligos • PFS • Polymeric depots • Obesity/ Diabetes • Peptides • Suspensions • Microspheres • Biologicals
Slide 43: Increased emphasis on complex injectables to add sustainable value
Increased emphasis on complex injectables to add sustainable value 1 Ease of use 2 Long acting depots 3 Complex molecules ▪ Ready-to-Use ▪ Suspensions ▪ Biosimilars ▪ Vancomycin RTU (launched) ▪ Triamcinolone, Betamethasone, ▪ Ustekinumab (filed) methylprednisolone, ▪ Daptomycin RT (launched) medrox
Slide 44: Agenda
Agenda Introduction R&D Manufacturing North America Commercial Europe Wrap-up Hikma Pharmaceuticals PLC 44
Slide 45: Our global footprint is expanding as we invest in increasing capacity
Our global footprint is expanding as we invest in increasing capacity and enhancing capabilities to support future growth embitions Injectables Manufacturing sites (Portugal and Cherry Hill being the largest sites in the Injectable Division) Spending c.$500m on Germany Injectables Bedford capex Ital
Slide 46: Local capacity and advanced manufacturing technologies enable us to respond to demand
Local capacity and advanced manufacturing technologies enable us to respond to increase in market demand and customer needs Europe United States MENA Small Liquid Parenteral Europe Terminal sterilization bags Injectable Hub with all technologies being Portugal is the largest Injectable facility Asep
Slide 47: We are expanding capacity and adding advanced technologies to drive high quality growth
We are expanding capacity and adding advanced technologies to drive high quality growth Capacity expansion: Injectables Manufacturing • Increasing liquid filling capacity by c.20% through addition of new lines • US Injectables products are largely produced at Hikma sites, with just 6% produced by 3r
Slide 48: Leverage core expertise, high efficient facilities and global presence to attract CMO customers
Leverage core expertise, high efficient facilities and global presence to attract CMO customers As we investing in expanding our manufacturing footprint, and with the additional capacity coming online, we are in active discussions with several potential future partners to sell the extra capacity whi
Slide 49: Agenda
Agenda Introduction R&D Manufacturing North America Commercial Europe Wrap-up Hikma Pharmaceuticals PLC 49
Slide 50: A top supplier with great relationships and broad portfolio
A top supplier with great relationships and broad portfolio Top 3 supplier by volume A broad and expanding portfolio 15 Products launched since 2016 launches contributed to 43.5% of 2024 17 US Injectables revenue launches Pfizer 16 12 Top three launches launches manufacturers 10 >100 active make up
Slide 51: Customer-centric go-to-market approach
Customer-centric go-to-market approach Key US Injectables customers Commercial infrastructure Commercial synergies Retail/wholesalers Utilize the expertise and relationships of the base business Government1 to drive additional sales in 503B and specialty • Traditional small • Products that molecules
Slide 52: Expanding our portfolio with dosage forms that bring value to our customers
Expanding our portfolio with dosage forms that bring value to our customers Broad portfolio of products today + planned RTDs Ready-to-administer (RTA) formulations ▪ Top three injectable portfolio in the ▪ Improves efficiency in hospitals – US market minimizes steps to administration of our products
Slide 53: Case study: VANCO READY – the first and only vancomycin RTU bag
Case study: VANCO READY – the first and only vancomycin RTU bag, with significant benefits vs. existing formulations. Patent protected to 2035 Product profile Benefits ▪ The first and only commercially available ▪ No need for dedicated compounding Survival rate of sepsis patients by time to ready-to
Slide 54: 503B Sterile Compounding – a compelling future growth opportunity
503B Sterile Compounding – a compelling future growth opportunity Why 503B is important to customers Hikma’s unique offering – A vertically integrated 503B compounder, backed by a sterile manufacturing company • Hikma purchased its Dayton 503B site in 2020 and has upgraded the facility to include 19
Slide 55: Hikma in Canada – leading growth in the generic hospital market
Hikma in Canada – leading growth in the generic hospital market 2024 generic Injectable sales (ex biotech)1,2,3 top 11 Hikma historical sales growth (in million $) 40% Bubble size: $ Sales 6 HIKMA 30% Top 11 = +34% 92% of total $ Sales CAGR 22-24 (%) 20% JUNO FRESENIUS Canada 2 average 10% PHARMASCI
Slide 56: Agenda
Agenda Introduction R&D Manufacturing North America Commercial Europe Wrap-up Hikma Pharmaceuticals PLC 56
Slide 57: Europe – Hikma showing strong growth in this large and highly fragmented market
Europe – Hikma showing strong growth in this large and highly fragmented market European Pharma Market – Total Value1 2024 Generic Injectable Sales (ex Biotech)2,3 – TOP 15 (in billion $) (in million $) 0 5 10 15 20 25 30 35 40 45 50 55 35 DR REDDYS Germany 30 10 EVER PHARMA Bubble size: $ Sales Fra
Slide 58: Hikma's growing presence across Europe
Hikma’s growing presence across Europe Hikma historical sales (excl contract manufacturing) Hikma markets (2021 - 2024 CAGR) (in million $) +18% 20 Molecules +63% 29 Molecules 26% CAGR 38% CAGR 66 Molecules 18% CAGR 33 Molecules 88% CAGR 65 Molecules 1% CAGR 2020 2021 2022 2023 2024 DE IT PT UK NL A
Slide 59: Agenda
Agenda Introduction R&D Manufacturing North America Commercial Europe Wrap-up Hikma Pharmaceuticals PLC 59
Slide 60: Injectables – well positioned for the future
Injectables – well positioned for the future Our strategy sets us up for continued success and supports our plan to deliver consistent profitable growth and our ambition to become leaders in all our markets Hikma Pharmaceuticals PLC 60
Slide 61: Group
Better health. Within reach. Every day. Hikma US Meet the Management Group
Slide 62: Our strategy for growth
Our strategy for growth operational efficiencies and embrace new technologies, maintaining our high-quality levels our broad portfolio and strong commercial capabilities a more differentiated pipeline into adjacent businesses and geographies our people and cultivate a unified culture responsibly acr
Slide 63: Our growth over the last 5 years has been supported by our strong foundation
Our growth over the last 5 years has been supported by our strong foundation Group historic 5-year historic Group historic revenue performance CAGR core operating profit performance 19% 2% 14% 10% (6)% (1)% 12% 9% 11% 6% Core revenue 7% Core operating profit 7% 2019 2020 2021 2022 2023 2024 2019 202
Slide 64: Our clear strategy supports our future growth ambitions
Our clear strategy supports our future growth ambitions Unlocking value through synergies across the organisation Investing to develop a more differentiated pipeline Operating sustainably to ensure we can deliver our purpose Engaging in strategic partnerships to accelerate growth Efficiency without
Slide 65: Navigating uncertainty and balancing opportunities and risks
Navigating uncertainty and balancing opportunities and risks Tariffs MFN Pricing US domestic Supply chain manufacturing complexity Shortages Hikma Pharmaceuticals PLC 65
Slide 66: Our focus on execution will deliver our medium-term targets
Our focus on execution will deliver our medium-term targets Our 3-year growth targets 2024 to 2027 Injectables Hikma Rx Branded • Expand our portfolio – • Maximise in-line portfolio • Deliver first-to–market Group maximise Xellia portfolio, • Enhance R&D launches revenue expand in Europe, launch gro
Slide 67: $5 billion Group revenue target in 2030
Our strategic plans, underpinned by significant investment, will enable us to achieve our Group revenue target of $5 billion in 2030 • Invest 5%-6% of Group revenue on R&D • Focusing on developing CMO as a core competency across • Extract synergies across our sites and business segments Group global
Slide 68: Q&A
Q&A Hikma Pharmaceuticals PLC